## Telemedicine for surgical site

# infection diagnosis: a systematic

## review protocol

- 4 Ross Lathan<sup>1\*</sup>, Misha Sidapra<sup>1</sup>, Marina Yiasemidou<sup>2</sup>, Judith Long<sup>1</sup>, Joshua Totty<sup>1</sup>, George
- 5 Smith<sup>1</sup>, Ian Chetter<sup>1</sup>

6

9

- 7 Academic Vascular Surgical Unit, Hull Royal Infirmary, Hull, United Kingdom
- 8 <sup>2</sup>Academic Clinical Lecturer, Bradford Teaching Hospitals, Bradford, United Kingdom
- 10 \*Corresponding Author
- 11 Email: ross.lathan2@nhs.net

13 *Identification:* Protocol for systematic review of diagnostic test accuracy 14 **Update:** Primary review 15 Registration and no.: Prospero ID - CRD42021290610 16 Version: 2.1 03/01/2022 17 18 Sponsor: Hull University Teaching Hospitals NHS Trust, R&D Department, Office 13, 2<sup>nd</sup> Floor Daisy 19 20 Building, Castle Hill Hospital, Castle Rd, Cottingham, East Yorkshire HU16 5JQ. 21 22 Hull University Teaching Hospitals 23 24 **NHS Trust** 25 26 The sponsor has not influenced the development of this protocol. 27 Funder: 28 Academic Department of Vascular Surgery, Hull Royal Infirmary 29 The funder has not influenced the development of this protocol. 30

31 Authors: 32 Ross Lathan: Corresponding Author 33 Protocol development, Literature search and screening, data extraction and 34 analysis, final review 35 Misha Sidapra: Hull University Teaching Hospitals NHS Trust 36 Literature search and screening, data extraction and analysis, final review 37 Marina Yiasemidou: Bradford University Teaching Hospitals NHS Trust 38 Final review drafting 39 Judith Long: Hull University Teaching Hospitals NHS Trust 40 Final review drafting 41 Joshua Totty: Hull University Teaching Hospitals NHS Trust 42 Protocol development, final review drafting George Smith: Hull University Teaching Hospitals NHS Trust 43 44 Final review drafting 45 lan Chetter: Hull University Teaching Hospitals NHS Trust 46 Final review drafting 47 48 49 50 51 52 53 54

55	Amendments						
56	Protocol version number will be annotated on the title page and thereby footer of each						
57	page. A list of major						
58	amendment changes to the protocol will be kept in the table below.						
	Amendment	Amendment Summary	Protocol Section				
	Number						
59							
60							
61							

### 62 Important Dates

Assessed as up to date	03/01/2022
Date of search	
Next stage expected	
Dustanal finat authlished	
Protocol first published	

#### **Definitions**

Surgical Site Infection An infection occurring after surgery in the part of the body

where surgery took place

Telemedicine The remote diagnosis and treatment of patients by means of

communications technology

Telehealth The delivery of healthcare services, where patients and providers

are separated by distance.

eHealth The use of information communication technology for health.

mHealth A component of eHealth where medical and public health

practices are supported by mobile devices.

Virtual Care All the ways healthcare providers remotely interact with their

patients

#### **Table of Contents**

65

66 67 BACKGROUND......8 68 2.1 69 2.2 70 2.3 CLINICAL PATHWAY 9 71 RATIONALE 11 2.4 72 73 2.5.1 74 2.5.2 75 3 76 PROTOCOL DEVELOPMENT 13 3.1 77 3.2 78 3.2.1 79 3.2.2 Participants 14 80 3.2.3 81 3.2.4 Target Condition 15 82 3.2.5 83 3.3 84 3 3 1 85 3.3.2 86 3.4 87 3.4.1 88 3.4.2 89 3.4.3 90 3.4.4 91 4 92 5 93 6 94 PRISMA-P (PREFERRED REPORTING ITEMS FOR SYSTEMATIC REVIEW AND META-ANALYSIS PROTOCOLS) 2015 6.1 95 96 97 6.3 98 6.4 99 6.5 100 101 102 103

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

Abstract Since the COVID-19 pandemic there has been a rapid uptake and utilisation of telemedicine in all aspects of healthcare. This presents a key opportunity in surgical site infection surveillance. Remote follow up methods have been used via telephone, with photographs and questionnaires for postoperative reviews with varying results. This review therefore aims to comprehensively synthesise available evidence for the diagnostic accuracy of all forms of SSI telemedicine monitoring. The protocol has been established as per both PRISMA-P and the Cochrane handbook for reviews of diagnostic test accuracy. Medline, Embase, CENTRAL and CINAHL will be searched using a complete search strategy developed with librarian input, in addition to google scholar and hand searching. All study designs with patients over 18 and undergone a primarily closed surgical procedure will be eligible. Index tests will include all forms of telemedicine and a subgroup analysis performed for each of these. Comparative tests must include face to face review, and all reference standards will be included again for sub-group analyses. Search results will be screened by two investigators independently with a third providing consensus review on disagreements. Methodological quality will be assessed using the QUADAS-2 tool, first validated by two investigators as per the Cochrane handbook. Exploratory analysis will formulate summary receiver operating characteristic curves and forest plots with estimates of sensitivity and specificity of the included studies. Sources of heterogeneity will be identifying and investigated through further analysis. Potential benefits of telemedicine integration in surgical practice will reduce cost and travel time to patients in addition to avoiding wasted clinic appointments, important considerations in a peripandemic era. To avoid missed or further complications, there must be confidence in the ability to diagnose infection. This review will systematically determine whether telemedicine is accurate for surgical site infection diagnosis, which methods are well established and if further research is indicated.

### 2 Background

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

2.1 Target condition being diagnosed This review primarily aims to identify surgical site infections (SSI). The Centre for Disease Control and Prevention (CDC) defines SSI as an infection within 30 days of an operation or up to 90 days if an implant is left in place and the infection is related to an operative procedure(1). SSI are further classified as 'superficial incisional SSI', 'deep incisional SSI', and 'organ/space SSI'; further details of these definitions can be found in appendix one(2). Surgical site infections complicate over 30% of operations, depending on the type of procedure(3, 4). Up to 60% of these present after discharge and so accurate and timely diagnosis requires intensive follow-up and potentially significant travel distances on the patient's behalf(5). For patients, SSI may have a significant impact on morbidity and mortality with subsequent time and cost implications(6). Unsurprisingly, the burden of infection encompasses healthcare providers too, with a recent UK study showing an association of SSI with a 92% increase in length of stay and an adjusted episode cost of £3040(7). Treatment for SSI can range from an oral course of antibiotics, to the need for reintervention (drainage or debridement), prolonged inpatient readmission and the subsequent risk of further morbidity (i.e. thrombotic and ischaemic events). 2.2 Index and Gold Standard Tests The current 'gold standard' for diagnosing SSI is a 'face-to-face' review using the US CDC criteria(2). However, other scoring systems or criteria may be used during a face-to-face review. The ASEPSIS score uses weighted, objectively measurable criteria to identify surgical

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

wounds as satisfactory healing, impaired wound healing or infected (appendix three)(8). A newly developed utility, the Bluebelle wound healing questionnaire (WHQ) has been validated in general surgery as a patient or clinician reported outcome measure to identify surgical site infection(9). Diagnosis of SSI using remote, digitally based contact between patients and clinicians (telemedicine) is being investigated as the primary index test in this review. In this review we are focussing on digital remote follow-up. There are many ways of implementing this in practice. These include the use of photographic images and/or video, either in real time or deferred, telephone review and instant messaging. There may be other novel methods not listed here that are identified during the review process. 2.3 Clinical Pathway Patients undergoing surgery may present with SSI at one of three typical time points. If an infection does occur, the first potential route of diagnosis is prior to discharge and within the first week. Infections at this point will depend on the surgical procedure, underlying comorbidities, and age, as these factors will influence typical length of stay (LOS) and wound healing. They are likely to be picked up on ward rounds or through dressing changes with the nursing team then highlighting issues to the surgeon. Face to face diagnosis using CDC criteria in this instance is straightforward as the patient has not left the department. The patient may have to undergo further observation, dressing changes and antibiotic course. Rarely, further imaging or intervention may be required.

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

The second point is typically patient initiated, after discharge but prior to any planned follow up, within 30 days of operation. Infections at this stage may not reach the surgeon's knowledge as they are often managed by the patient's primary care physician. However, without specialist input some infections progress in severity. Patients with evidence of deep incisional or organ/space infections may be referred to secondary care by the primary care team, may present to the emergency department or may contact the surgical team directly through an aftercare number. Only once seen can the gold standard assessment take place. Further imaging, microbiology culture and sensitivity testing are often implemented to ensure appropriate and specific management. Further surgical intervention may be required. Finally, patients may not be contemporaneously identified as having SSI. Delayed or missed mild SSI diagnosis may present when the patient arrives in clinic for review (often after 30 days postoperatively, or if this is telephonic, it may be apparent through the history). Patients with more severe infection usually will have presented at the emergency department by this point, but if missed can impact on morbidity. Management will focus on ensuring no ongoing infection and alleviating further complications. Index tests in this setting will likely be used as a comparative to face-to-face, gold standard review at planned review points. Potential implications of digital remote follow up are early and avoidance of missed diagnosis within the 30-day window for the CDC criteria.

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

2.4 Rationale Widespread technological innovation and adoption have been exponential in the 21<sup>st</sup> century. Sophistication of the mobile phone now allows for instantaneous communication all over the planet. Users can even transfer image and video data in real time. In 2019, 88% of individuals in the UK were estimated to own a smartphone (10). Naturally, the use of technology in healthcare has too progressed. Telemedicine is the remote diagnosis and treatment of patients by use of technology(11). Coined in the 1970s, this concept has broadened with the advent of the smartphone and mobile data. Mobile health (mHealth) is a contemporary classification whereby healthcare is supported by the use of mobile devices(12). The use of telemedicine has enabled patients in isolated centres access to specialist review through transfer of medical imaging, and teleconsultations are coming into practice(13). In surgery, the process of postoperative care is changing with the introduction of telemedicine. In 2020, the COVID-19 pandemic caused a countrywide lockdown in the UK, and many other countries all over the world. Elective operations were cancelled, expanding already lengthy waiting lists. This also posed a challenge for outpatient follow up, as patients requiring review would be at risk of COVID-19 in attending the hospital, and departments adapted to comply with social distancing regulations, limiting the number of people allowed in outpatient spaces at any one time. Remote follow-up has the potential to reduce unnecessary clinic visits providing benefits for

both patients and healthcare providers. The rationale of this review, therefore, is to

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

synthesise the current available evidence for using telemedicine to diagnose or exclude SSI in the context of post-operative follow up. 2.5 Objectives 2.5.1 Research Question Primary: Is digital remote follow-up accurate for the diagnosis of surgical site infection? Secondary: - What methods are used to facilitate SSI diagnosis? What are the limitations of telemedicine in SSI diagnosis? This systematic review aims to assess the diagnostic accuracy of using telemedicine to identify SSI post-operatively. It will also aim to identify which methods are currently in use for this and any limitations of telemedicine methods in SSI diagnosis. 2.5.2 Objectives Primary: To determine the diagnostic accuracy of digital remote follow-up for the diagnosis of surgical site infection Secondary objectives To determine what methods of digital remote follow-up have been used Evaluate the accuracy of different digital remote follow-up methods To determine limitations of digital remote follow-up

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

3 Methods 3.1 Protocol Development This protocol and review have been developed using the Cochrane handbook for reviews of diagnostic test accuracy and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statements (14, 15). In addition, this protocol is reported in line with the PRISMA statement for review protocols (PRISMA-P) which is attached in appendix one(15). 3.2 Criteria for considering studies for this review 3.2.1 Types of studies There will be no restrictions on inclusion based upon prospective or retrospective study designs, however given the nature of the novel interventions, it is unlikely that retrospective studies will be available. Study designs which result in measures of test accuracy will be included, including randomised and observational studies. There will be no limitations on study sample sizes, or quality to thoroughly synthesise the available literature, but this will be accounted for in a quality of evidence assessment. All study types will be included, and a sub group analysis performed for direct, fully paired and randomised studies. Narrative and systematic review articles, letters and opinion pieces will be excluded from this review, however the reference lists of review articles will be hand searched for completeness.

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

3.2.2 Participants All patients over 18, who have undergone a procedure involving surgical incisions and followed up in a postoperative pathway will be eligible. Studies involving children under the age of 18 years and written in language other than English will be excluded from the review. The study setting will vary depending on whether the index or reference test is being examined. The index tests can be performed anywhere as they are remote, the reference will be in a secondary care setting, likely clinics. The index and reference tests will be applied on clinical assessment and on suspicion of surgical wound infection, no prior tests are required. 3.2.3 Index and Comparative Tests The index test to be reviewed is digital remote follow-up. Telemedicine is the remote diagnosis or treatment of patients using communications technology, which encompasses the term digital remote follow-up and will be used as a synonym in this review. Specifically, this entails the use of photographs or video, either deferred or in real time, telephone review and/or instant messaging. All index test methods will be evaluated through subgroup analyses. The comparative tests are face to face review with the patient to directly observe the wound and obtain a history.

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

3.2.4 Target Condition Surgical site infection as defined by CDC is the target condition for this review; infection within 30 days of surgery or within 90 days if an implant is left in place. This is further discussed in section 1.1. Some studies may categorise this further into superficial, deep and organ/space SSI (more details in appendix two). 3.2.5 Reference Standards The same diagnostic criteria will be used for both tests. The gold standard for assessment of SSI is the US CDC criteria which clearly define indication of infection. Other possible methods are the ASEPSIS score with infection clearly define at a score of 21 or greater, and bluebelle WHQ. The latter has been suggested with an infection cut off score of 6-8. All methods of remote diagnosis will be extracted and a sub-group analysis performed for each type. 3.3 Search Methods for Identification of Studies 3.3.1 Electronic searches Medline, Embase, CENTRAL and CINAHL databases will be searched from inception to the current date. Additional resources will be identified through google scholar. 3.3.2 Searching other sources Additional searches will be conducted through handsearching the reference lists of included articles and excluded review articles. An example search strategy is provided in appendix five.

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

3.4 Data Collection and Analysis 3.4.1 Selection of Studies Search results will be deduplicated and uploaded to the specialised online review tool, Rayyan. Study titles and abstracts will be screened by two investigators, RL and MS, independently. Any disagreement will be resolved by consensus decision from a third investigator. Articles included at this stage will be retrieved for full text screening, again by two authors acting independently. Those included after full text screening will go on to data extraction. 3.4.2 Data extraction and management Data extraction will be into a bespoke designed spreadsheet (Microsoft Excel), hosted remotely and updated in real-time. Information on study design, country of origin, participant age and gender, sample size, surgery performed, drop out rates, time to followup and type of remote follow-up (photograph / video / telephone / other) will be extracted. Details on infection rates for remote and face to face methods as well as sensitivity and specificity of diagnosis will also be extracted. If information is available on specifics of superficial, deep and organ/space SSI rates, these data will also be extracted. 3.4.3 Assessment of methodological quality Methodological quality will be assessed using the QUADAS-2 tool (appendix four)(16). Due to the nature of varying study design, systematic reviews of diagnostic test accuracy are often prone to heterogenous results. In 2003, the quality assessment of diagnostic studies (QUADAS) tool was developed. This has since been revised as QUADAS-2 and is

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

recommended for use in such reviews by the Agency for Healthcare Research and Quality, Cochrane Collaboration, and the UK National Institute for Health and Clinical Excellence (16). Two authors will assess each manuscript as per the QADAS-2 tool, with a third independent author providing consensus review when discrepancies occur. Further details on the QUADAS-2 process can be found in appendix four. 3.4.4 Statistical analysis and data synthesis SSI diagnosed using any diagnostic criteria as part of a face-to-face review will be the reference standard. The patient will be the unit of analysis. Forest plots and receiver operating characteristic (ROC) curves will be produced as part of the initial, exploratory analysis and used to display estimates of sensitivity and specificity of the included studies. Summary measures of sensitivity and specificity will be produced using a bivariate model for meta-analysis, if there are sufficient studies. Receiver Operator Characteristic Curves Summary receiver operator characteristic (sROC) curves will be plotted using each study included as a data point. Confidence regions will also be calculated. Plots will be produced using metaDTA(17). Sensitivity Analysis Sensitivity analysis based upon risk of bias will be evaluated. Studies with a high or unclear risk of bias identified by the QADAS-2 tool will be excluded in a separate analysis.

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376

377

378

379

Assessment of Heterogeneity Several sources of potential heterogenetive have been identified, and their effects will be investigated through the use of subgroup analysis and metaregression. The diagnostic criteria used to diagnose SSI (CDC, ASEPSIS, Bluebelle WHQ or others) may influence the test accuracy as different tools have been found to have poor correlation(18). Discussion Integration of telemedicine has multiplied in recent years, exponentially so in response to the COVID-19 pandemic. One prospective application is remote diagnosis of SSI. Consolidation of telemedicine in surgical practice has the potential to reduce cost to both patient and care provider, as well as improved time implications for both parties. This would also reduce unnecessary visits to hospital clinic with a healthy surgical wound, an important consideration during a pandemic. To avoid further complications however and allow for confidence in diagnosis, telemedicine must be accurate in the detection of SSI. Previous studies have shown erythema detection to be difficult in review of wound images compare to face to face, which may influence a diagnosis of infection(19). This review aims to comprehensively examine the accuracy for all methods of remote diagnosis of SSI thereby enabling evidence-based decision making on remote reviews of post-operative patients.

5 References

- 381 1. Centres for Disease Control and Prevention (CDC). Surgical Site Infection (SSI) Event
- 382 2017 [Available from: https://www.cdc.gov/nhsn/pdfs/pscmanual/9pscssicurrent.pdf.
- 383 2. Horan TC, Gaynes RP, Martone WJ, Jarvis WR, Emori TG. CDC definitions of
- 384 nosocomial surgical site infections, 1992: a modification of CDC definitions of surgical
- wound infections. Infect Control Hosp Epidemiol. 1992;13(10):606-8.
- 386 3. GlobalSurg Collaborative. Determining the worldwide epidemiology of surgical site
- infections after gastrointestinal resection surgery: protocol for a multicentre, international,
- prospective cohort study (GlobalSurg 2). BMJ Open,. 2017;7:e012150.
- 389 4. Saeed MJ, Dubberke ER, Fraser VJ, Olsen MA. Procedure-specific Surgical Site
- 390 Infection Incidence Varies Widely within Certain National Healthcare Safety Network
- 391 Surgery Groups. American Journal of Infection Control. 2015;43((6)):617-23.
- Woelber E, Schrick EJ, Gessner BD, Evans HL. Proportion of Surgical Site Infections
- Occuring after Hospital Discharge: A Systematic Review. Surgical Infections. 2016;17(5).
- 394 6. Astagneau P, Rioux C, Golliot F, Brücker G. Morbidity and mortality associated with
- surgical site infections: results from the 1997-1999 INCISO surveillance. J Hosp Infect.
- 396 2001;48(4):267-74.
- 397 7. Totty JP, Moss JWE, Barker E, Mealing SJ, Posnett JW, Chetter IC, et al. The impact of
- 398 surgical site infection on hospitalisation, treatment costs, and health-related quality of life
- after vascular surgery. International Wound Journal. 2020;18(3):261-8.
- 400 8. Wilson AP, Treasure T, Sturridge MF, Grüneberg RN. A scoring method (ASEPSIS) for
- 401 postoperative wound infections for use in clinical trials of antibiotic prophylaxis. Lancet.
- 402 1986;1(8476):311-3.

- 403 9. Validation of the Bluebelle Wound Healing Questionnaire for assessment of surgical-
- site infection in closed primary wounds after hospital discharge. Br J Surg. 2019;106(3):226-
- 405 35.
- 406 10. Deloitte. Global Mobile Consumer Survey: UK cut 2019 [Available from:
- 407 https://www2.deloitte.com/content/dam/Deloitte/uk/Documents/technology-media-
- 408 telecommunications/deloitte-uk-plateauing-at-the-peak-the-state-of-the-smartphone.pdf.
- 409 11. WHO. Telemedicine Opportunities and developments in Member States. 2010.
- 410 12. WHO. mHealth: New horizons for health through mobile technologies.: World Health
- 411 Organisation; 2011.
- 412 13. Maani R, Camorlinga S, Eskicioglu R. A Remote Real-time PACS-based Platform for
- 413 Medical Imaging Telemedicine. Proceeding of SPIE. 2009;7264.
- 414 14. Cochrane. Cochrane Handbook for Systematic Reviews of Diagnostic Test Accuracy.
- 415 Cochrane Training; 2021.
- 416 15. Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred
- 417 reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015
- 418 statement. Systematic Reviews. 2015;4(1):1.
- 419 16. Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al.
- 420 QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann
- 421 Intern Med. 2011;155(8):529-36.
- 422 17. Freeman SC, Kerby CR, Patel A, Cooper NJ, Quinn T, Sutton AJ. Development of an
- 423 interactive web-based tool to conduct and interrogate meta-analysis of diagnostic test
- 424 accuracy studies: MetaDTA. BMC Medical Research Methodology. 2019;19(1):81.

Wilson AP, Gibbons C, Reeves BC, Hodgson B, Liu M, Plummer D, et al. Surgical wound infection as a performance indicator: agreement of common definitions of wound infection in 4773 patients. Bmj. 2004;329(7468):720.
Totty JP, Harwood AE, Wallace T, Smith GE, Chetter IC. Use of photograph-based telemedicine in postoperative wound assessment to diagnose or exclude surgical site infection. Journal of wound care. 2018;27(3):128-35.

## 6 Appendix / Supporting Information

433

434

435

436

437

## 6.1 PRISMA-P (Preferred Reporting Items for Systematic review and Meta-

Analysis Protocols) 2015 Checklist: recommended items to address in a

systematic review protocol(15)

Section and Topic	Item No.	Checklist Item			
Administrative information					
Title					
Identification	1a	Identify the report as a protocol of a systematic review			
Update	1b	If the protocol is for an update of a previous systematic review, identify as such			
Registration	2	If registered, provide the name of the registry (such as PROSPERO) and			
		registration number			
Authors:					
Contact	3a	Provide name, institutional affiliation, e-mail address of all protocol authors;			
		provide physical mailing address of corresponding author			
Contributions	3b	Describe contributions of protocol authors and identify the guarantor of the			
		review			
Amendments	4	If the protocol represents an amendment of a previously completed or			
		published protocol, identify as such and list changes; otherwise, state plan for			
		documenting important protocol amendments			
Support					
Sources	5a	Indicate sources of financial or other support for the review			
Sponsor	5b	Provide name for the review funder and/or sponsor			
Role of sponsor or	5c	Describe roles of funder(s), sponsor(s), and/or institution(s), if any, in			
funder		developing the protocol			
Introduction					

Rationale	6	Describe the rationale for the review in the context of what is already known
Objectives	7	Provide an explicit statement of the question(s) the review will address with
		reference to participants, interventions, comparators, and outcomes (PICO)
Methods		
Eligibility criteria	8	Specify the study characteristics (such as PICO, study design, setting, time
		frame) and report characteristics (such as years considered, language,
		publication status) to be used as criteria for eligibility for the review
Inforamtion sources	9	Describe all intended information sources (such as electronic databases,
		contact with study authors, trial registers or other grey literature sources) with
		planned dates of coverage
Search strategy	10	Present draft of search strategy to be used for at least one electronic database,
		including planned limits, such that it could be repeated
Study records		
Data management	11a	Describe the mechanism(s) that will be used to manage records and data
		throughout the review
Selection process	11b	State the process that will be used for selecting studies (such as two
		independent reviewers) through each phase of the review (that is, screening,
		eligibility and inclusion in meta-analysis)
Data collection	11c	Describe planned method of extracting data from reports (such as piloting
process		forms, done independently, in duplicate), any processes for obtaining and
		confirming data from investigators
Data items	12	List and define all variables for which data will be sought (such as PICO items,
		funding sources), any pre-planned data assumptions and simplifications
Outcomes and	13	List and define all outcomes for which data will be sought, including
prioritisations		prioritization of main and additional outcomes, with rationale
Risk of bias in	14	Describe anticipated methods for assessing risk of bias of individual studies,
individual studies		including whether this will be done at the outcome or study level, or both;
		state how this information will be used in data synthesis

15a	Describe criteria under which study data will be quantitatively synthesised
15b	If data are appropriate for quantitative synthesis, describe planned summary
	measures, methods of handling data and methods of combining data from
	studies, including any planned exploration of consistency (such as I2, Kendall's
	τ)
15 c	Describe any proposed additional analyses (such as sensitivity or subgroup
	analyses, meta-regression)
15d	If quantitative synthesis is not appropriate, describe the type of summary
	planned
16	Specify any planned assessment of meta-bias(es) (such as publication bias
	across studies, selective reporting within studies)
17	Describe how the strength of the body of evidence will be assessed (such as
	GRADE)
	15b 15c 15d

6.2 SSI Classification 440 441 442 Superficial incisional infection 443 Defined as a surgical site infection occurring within 30 days of surgery and involves only the 444 skin or subcutaneous tissue of the incision, and meets at least one of the following criteria: 445 446 Criterion 1: Purulent drainage from the superficial incision. 447 448 Criterion 2: The superficial incision yields organisms from the culture of aseptically 449 aspirated fluid or tissue, or from a swab and pus cells are present. 450 451 Criterion 3: At least two of the following symptoms and signs: 452 - pain or tenderness 453 - localised swelling 454 - redness 455 - heat 456 AND a. the superficial incision is deliberately opened by a surgeon to manage the infection, 457 unless the incision is culture-negative 458 OR b. the clinician diagnoses a superficial incisional infection. 459 Note: Stitch abscesses are defined as minimal inflammation and discharge confined to the 460 points of suture penetration, and localised infection around a stab wound. They are not 461 classified as surgical site infections. 462 463

465

466

467

468

469

470

471

472

473

474

475

476

477

478

479

480

481

482

483

484

485

486

Deep incisional infection Defined as a surgical site infection involving the deep tissues (i.e. fascial and muscle layers) that occurs within 30 days of surgery if no implant is in place, or within 90 days if an implant is in place and the infection appears to be related to the surgical procedure, and meets at least one of the following criteria: Criterion 1: Purulent drainage from the deep incision but not from the organ/space component of the surgical site. Criterion 2: The deep incision yields organisms from the culture of aseptically aspirated fluid or tissue, or from a swab and pus cells are present. Criterion 3: A deep incision that spontaneously dehisces or is deliberately opened by a surgeon when the patient has at least one of the following symptoms or signs (unless the incision is culture negative): - fever (>38°C) - localised pain or tenderness Criterion 4: An abscess or other evidence of infection involving the deep incision that is found by direct examination during re-operation, or by histo-pathological or radiological examination. Criterion 5: Diagnosis of a deep incisional surgical site infection by an attending clinician.

488

489

490

491

492

493

494

495

496

497

498

499

500

501

502

503

504

505

506

507

508

Note: An infection involving both superficial and deep incision is classified as deep incisional SSI unless there are different organisms present at each site. Organ/space infection Defined as a surgical site infection involving any part of the anatomy (i.e. organ/space), other than the incision, opened or manipulated during the surgical procedure, that occurs within 30 days of surgery if no implant is in place, or within 90 days if an implant is in place and the infection appears to be related to the surgical procedure, and meets at least one of the following criteria: Criterion 1: Purulent drainage from a drain that is placed through a stab wound into the organ/space. Criterion 2: The organ/space yields organisms from the culture of aseptically aspirated fluid or tissue, or from a swab and pus cells are present. Criterion 3: An abscess or other evidence of infection involving the organ/space that is found by direct examination, during re-operation, or by histo-pathological or radiological examination. Criterion 4: Diagnosis of an organ/space infection by an attending clinician

Note: 1. Occasionally, an organ/space infection drains through the incision. Such infection generally does not require re-operation and is considered to be a complication of the incision, and is therefore classified as a deep incisional infection.

2. Where doubt exists, refer to the Definitions of specific site of organ/space infection to determine if the organ/space infection meets the definition

### 6.3 Asepsis Score

515

516

517

519

### Scores awarded for ASEPSIS components

	Score
Wound characteristic	
Serous exudates	3
Erythema	3
Purulent exudates	6
Separation of wound edges	6
Additional treatment	
Postoperative Antibiotics	10
Abscess drainage	5
Wound debridement	10
Isolation of bacteria	10
Prolonged stay/admission to hospital	5

- An ASEPSIS score of ≥21 is taken as indicating the presence of infection, whilst a score of ≤
- 518 **10** is taken to represent satisfactory healing.

521

522

523

524

525

526

527

528

529

530

531

532

533

534

535

536

537

538

539

540

541

542

543

6.4 QUADAS-2 The process occurs in four phases; 1. Statement of the review question This involves a summary of the review at hand in the form of patients, index tests, reference standards and target condition, details of which can be found in sections 2.2.2 - 2.2.5. 2. Validation of QUADAS-2 tool Both authors will utilise the tool in two example papers to be included as suggested in the QUADAS-2 supporting material. Agreement of 80% or more across all categories will be taken as sufficient and QUADAS-2 taken forward for assessment of all studies. Insufficient agreement will lead to further refinement of the tool through addition or omitting signalling questions and the process repeated until agreement is satisfactory. 3. Flow diagram The primary study's flow diagram will be taken (or synthesised if not provided) to facilitate judgments of risk of bias in phase four. This will provide information on the method of patient recruitment, the order of test execution, the number of patients undergoing the index test and reference standard 4. Judgments on bias and applicability Risk of Bias The tool itself comprises four separate domains, the first section of each concerns bias and has three sections.

545

546

547

548

549

550

551

552

553

554

555

556

557

558

559

560

561

562

563

564

565

566

Information used to support the risk of bias judgment; to make the rating transparent and can aid discussion between independent review authors Signalling questions; presented to assist judgements. Answered 'yes', 'no', or 'unclear' so that 'yes' would indicate a low risk of bias. Judgement of the risk of bias; 'low', 'high', or 'unclear'. If all signalling questions are answered 'yes' then risk of bias is to be judged as 'low'. If any signalling question returns 'no' there would be potential for bias. The guidelines from phase two will assist authors in the judgement. 'Unclear' should only be used if insufficient data are reported to allow a judgement. **Applicability** These sections do not include signalling questions. Authors should record information on which the applicability judgement is made and then rate their concern that the study does not match the review question. This can be rated as 'low', 'high' or 'unclear'. Again, 'unclear' is only to be used when insufficient data are available. Guidance for completing the QUADAS-2 tool **Domain 1: Patient Selection** Risk of bias: Could the selection of patients have introduced bias? Was a consecutive or random sample of patients enrolled? Was a case control design avoided? Did the study avoid inappropriate exclusions?

568

569

570

571

572

573

574

575

576

577

578

579

580

581

582

583

584

585

586

587

588

589

590

Ideally studies should enrol all consecutive or a random sample of patients undergoing surgery, otherwise there is potential for bias. Inappropriate exclusions (difficult diagnosis) may skew estimates of diagnostic accuracy. Enrolment of patients with known SSI may also exaggerate diagnostic accuracy. Applicability: Are there concerns that the included patients and setting do not match the review question? Patients included in the study should match those in the review question to ensure applicability of results. This can be in terms of SSI severity, demographics, comorbidity, study setting. **Domain 2: Index Text** Risk of Bias: Could the conduct or interpretation of the index test have introduced bias? Were the index test results interpreted without knowledge of the results of the reference standard? If a threshold was used, was it pre-specified The first signalling question refers to blinding, and the potential for bias with regards to testing order. If the index test is always conducted and interpreted prior to the reference standard, then this item can be rated 'yes'. The second question depends on the method of telemedicine used. If bluebelle WHQ is used in any of the methods this should be indicated what the cut off for SSI is. Applicability: Are there concerns that the index test, it's conduct, or interpretation differ from the review question?

592

593

594

595

596

597

598

599

600

601

602

603

604

605

606

607

608

609

610

611

612

613

Variations in test technology, execution or interpretation may affect estimates of it's diagnostic accuracy. If these vary from those specified in the review question there may be concerns of applicability. **Domain 3: Reference Standard** Risk of Bias: Could the reference standard, its conduct, or its interpretation have introduced bias? Is the reference standard likely to correctly classify the target condition? Were the reference standard results interpreted without knowledge of the results of the index test? What version of the reference standard was used? CDC / ASEPSIS / Bluebelle / other? How likely is that to have correctly identify SSI? Potential for bias is related to the potential influence of prior knowledge on the interpretation of the reference standard, similar to that in domain two. Applicability: Are there concerns that the target condition as defined by the reference standard does not match the question? The target condition, SSI, defined by the reference standard, may differ from the SSI specified in the review question. **Domain 4: Flow and Timing** Risk of Bias: Could the patient flow have introduced bias? Was there an appropriate interval between index test and reference standard?

615

616

617

618

619

620

621

622

623

624

625

626

627

628

629

630

631

632

633

634

635

636

Ideally results on the index test and reference standard are collected on the same patient at the same time. Delay or initiation of treatment between one of the two tests may result in misclassification due to recovery or deterioration in SSI criteria. Did all patients receive the same reference standard? Verification bias occurs when not all the study patients receive confirmation of diagnosis by the same reference standard. Were all patients included in the analysis? All patients recruited into the study should be included in the analysis. If the number of patients enrolled differs from the number of patients included in the 2x2 table of results, there is potential for bias. Presentation of QUADAS-2 results Overall generalisable statements of 'low' or 'high risk of bias' will not be used unless a study is judged to be 'low' across all domains or if the study has been judged 'high' or 'unclear' in one or more domains it may be at risk of bias or as having concerns regarding applicability. Results will be presented in the following cross tabulation whereby '+' indicates high risk or concern, '-' indicates low risk or concern and '?' indicates unclear.

	Risk of bias			Applicability Concerns			
Study	Patient	Index	Reference	Flow and	Patient	Index	Reference
	Selection	Test	Standard	Timing	Selection	Test	Standard
Study 1	+/-/?	+/-/?	+/-/?	+/-/?	+/-/?	+/-/?	+/-/?
Study 2	+/-/?	+/-/?	+/-/?	+/-/?	+/-/?	+/-/?	+/-/?
Study 3	+/-/?	+/-/?	+/-/?	+/-/?	+/-/?	+/-/?	+/-/?
	+/-/?	+/-/?	+/-/?	+/-/?	+/-/?	+/-/?	+/-/?

Table 1: Representation of tabulation for QUADAS-2 analysis on systematic review studies.

Recommended quality items derived from QUADAS tool

637

638

639

- Was the spectrum of patients representative of the patients who will receive the test in practice? (representative spectrum)
- Is the reference standard likely to classify the target condition correctly?
   (acceptable reference standard)
- 3. Is the time period between reference standard and index test short enough to be reasonably sure that the target condition did not change between the two tests? (acceptable delay between tests)
- 4. Did the whole sample or a random selection of the sample, receive verification using the intended reference standard? (partial verification avoided)
- Did patients receive the same reference standard irrespective of the index result?
   (differential verification avoided)

- 6. Was the reference standard independent of the index test (i.e the index test did not form part of the reference standard) incorporation avoided)
- 7. Were the reference standard results interpreted without knowledge of the results of the index test? (index test results blinded)
- 8. Were the index test results interpreted without knowledge of the results of the reference standard (reference standard results blinded)
- 9. Were the same clinical data available when test results were interpreted as would be available when the test is used in practice? (relevant clinical information)
- Were uninterpretable/intermediate test results reported? (uninterpretable results reported)
- 11. Were withdrawals from the study explained? (withdrawals explained)
  Additional items
- 12. Is the technology of the index test unchanged since the study was carried out?
- 13. Did the study provide a clear definition of what was considered to be a positive result?
- 14. Were data on observer variation reported and within an acceptable range?
- 15. Was treatment withheld until both the index test and reference standard were performed?
- 16. Were objectives pre-specified?

(exp (Telemedicine)/ OR (remote consultation).mp OR (teleconsultation).mp OR (teleconsultation).mp OR (teleconsultation).mp OR (mobile health).mp OR (telehealth).mp OR (ehealth).mp OR (mhealth).mp OR (telephon\*).mp OR (photograph\*).mp OR (video\*).mp OR (mobile app\*).mp)

AND

(exp (surgical wound infection)/ OR (surgical wound dehiscence).mp OR surgical site infection).mp OR (postoperative infection).mp OR (SSI).mp OR (wound infection).mp OR (surgical wound complication).mp OR (post-surgical infection).mp OR (post operative infection).mp OR (post-operative infection).mp)